Company profile
CELLECTAR BIOSCIENCES, INC.
NASDAQ:CLRBBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IOPOFOSINE I-131 | phase3 | — | 7 | active |
| OXIGLUTATIONE DISODIUM | phase3 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01058512 | phase2 | completed | 2010-03-01 | 2010-12-01 | Cellectar Biosciences, Inc. | A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy |
| NCT03478462 | phase1 | active_not_recruiting | 2019-04-30 | 2027-06-30 | Cellectar Biosciences, Inc. | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas |
| NCT02278315 | phase1 | completed | 2015-02-01 | 2020-12-09 | Cellectar Biosciences, Inc. | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT01495663 | phase1 | completed | 2011-12-01 | 2013-11-01 | Cellectar Biosciences, Inc. | Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned |
| NCT00925275 | phase1 | completed | 2009-06-01 | 2010-02-01 | Cellectar, Inc | Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors |
FDA applications (0)
No records yet.